Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Dreyling

Showing results (191-200 of 336) with videos related to

Pageof 34
Sort By:
Neuro-Oncology Advances|February 16, 2026
Time matters: The prognostic impact of diagnostic delay on survival in primary central nervous system lymphoma-a single-center, retrospective real-world studyLouisa Lehner, Louisa von Baumgarten, Jonas Reis, et al.
Blood Advances|February 9, 2021
Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphomaPanayiotis Panayiotidis, George A Follows, Luigina Mollica, et al.
Blood|September 2, 2006
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)Roswitha Forstpointner, Michael Unterhalt, Martin Dreyling, et al.
Blood|December 8, 2005
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphomaChristiane Pott, Carsten Schrader, Stefan Gesk, et al.
British Journal of Haematology|August 24, 2017
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studiesSimon Rule, Martin Dreyling, Andre Goy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvementGerhard Held, Samira Zeynalova, Niels Murawski, et al.
Transplantation|January 12, 2012
Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder RegistryHeiner Zimmermann, Ilske Oschlies, Susanne Fink, et al.
Leukemia & Lymphoma|November 30, 2012
High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signatureTobias Herold, Medhanie A Mulaw, Vindi Jurinovic, et al.
Leukemia & Lymphoma|February 10, 2010
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomasEckhart Weidmann, Georg Hess, Kai U Chow, et al.
Hemasphere|July 11, 2020
Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular LymphomaGeorg Hess, Karola Wagner, Ulrich Keller, et al.
Pageof 34

Showing results (191-200 of 336) with videos related to

Sort By:
Pageof 34
Neuro-Oncology Advances|February 16, 2026
Time matters: The prognostic impact of diagnostic delay on survival in primary central nervous system lymphoma-a single-center, retrospective real-world studyLouisa Lehner, Louisa von Baumgarten, Jonas Reis, et al.
Blood Advances|February 9, 2021
Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphomaPanayiotis Panayiotidis, George A Follows, Luigina Mollica, et al.
Blood|September 2, 2006
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)Roswitha Forstpointner, Michael Unterhalt, Martin Dreyling, et al.
Blood|December 8, 2005
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphomaChristiane Pott, Carsten Schrader, Stefan Gesk, et al.
British Journal of Haematology|August 24, 2017
Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studiesSimon Rule, Martin Dreyling, Andre Goy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvementGerhard Held, Samira Zeynalova, Niels Murawski, et al.
Transplantation|January 12, 2012
Plasmablastic posttransplant lymphoma: cytogenetic aberrations and lack of Epstein-Barr virus association linked with poor outcome in the prospective German Posttransplant Lymphoproliferative Disorder RegistryHeiner Zimmermann, Ilske Oschlies, Susanne Fink, et al.
Leukemia & Lymphoma|November 30, 2012
High expression of MZB1 predicts adverse prognosis in chronic lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma and is associated with a unique gene expression signatureTobias Herold, Medhanie A Mulaw, Vindi Jurinovic, et al.
Leukemia & Lymphoma|February 10, 2010
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomasEckhart Weidmann, Georg Hess, Kai U Chow, et al.
Hemasphere|July 11, 2020
Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular LymphomaGeorg Hess, Karola Wagner, Ulrich Keller, et al.
Pageof 34